Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 2/2014

Open Access 01-02-2014 | Therapy in Practice

Managing Therapeutic Competition in Patients with Heart Failure, Lower Urinary Tract Symptoms and Incontinence

Authors: Cara Tannenbaum, Kristina Johnell

Published in: Drugs & Aging | Issue 2/2014

Login to get access

Abstract

Up to 50 % of heart failure patients suffer from lower urinary tract symptoms. Urinary incontinence has been associated with worse functional status in patients with heart failure, occurring three times more frequently in patients with New York Heart Association Class III and IV symptoms compared with those with milder disease. The association between heart failure and urinary symptoms may be directly attributable to worsening heart failure pathophysiology; however, medications used to treat heart failure may also indirectly provoke or exacerbate urinary symptoms. This type of drug–disease interaction, in which the treatment for heart failure precipitates incontinence, and removal of medications to relieve incontinence worsens heart failure, can be termed therapeutic competition. The mechanisms by which heart failure medication such as diuretics, angiotensin-converting enzyme (ACE) inhibitors and β-blockers aggravate lower urinary tract symptoms are discussed. Initiation of a prescribing cascade, whereby antimuscarinic agents or β3-agonists are added to treat symptoms of urinary urgency and incontinence, is best avoided. Recommendations and practical tips are provided that outline more judicious management of heart failure patients with lower urinary tract symptoms. Compelling strategies to improve urinary outcomes include titrating diuretics, switching ACE inhibitors, treating lower urinary tract infections, appropriate fluid management, daily weighing, and uptake of pelvic floor muscle exercises.
Literature
1.
Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370:185–91.PubMedCrossRef
2.
Xu D, Kane RL. Effect of urinary incontinence on older nursing home residents’ self-reported quality of life. J Am Geriatr Soc. 2013;61(9):1473–81
3.
4.
Seferovic PM, Stoerk S, Filippatos G, Mareev V, Kavoliuniene A, Ristic AD, et al. Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. Eur J Heart Fail. 2013;15:947–59.PubMedCrossRef
5.
Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352–60.PubMedCrossRef
6.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.PubMedCrossRef
7.
DuBeau CE, Kuchel GA, Johnson T 2nd, Palmer MH, Wagg A. Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence. Neurourol Urodyn. 2010;29:165–78.PubMedCrossRef
8.
Hwang R, Chuan F, Peters R, Kuys S. Frequency of urinary incontinence in people with chronic heart failure. Heart Lung. 2013;42:26–31.PubMedCrossRef
9.
Lindeman K, Li Y, Palmer MH. Help-seeking for incontinence by individuals with heart failure. J Am Geriatr Soc. 2012;60:1994–5.PubMedCrossRef
10.
Lee PG, Cigolle C, Blaum C. The co-occurrence of chronic diseases and geriatric syndromes: the health and retirement study. J Am Geriatr Soc. 2009;57:511–6.PubMedCrossRef
11.
Madigan EA, Gordon N, Fortinsky RH, Koroukian SM, Pina I, Riggs JS. Predictors of functional capacity changes in a US population of Medicare home health care (HHC) patients with heart failure (HF). Arch Gerontol Geriatr. 2012;54:e300–6.PubMedCentralPubMedCrossRef
12.
Palmer MH, Hardin SR, Behrend C, Collins SK, Madigan CK, Carlson JR. Urinary incontinence and overactive bladder in patients with heart failure. J Urol. 2009;182:196–202.PubMedCrossRef
13.
Balta S, Kurt O, Cakar M, Demirkol S, Unlu M, Kucuk U. Urinary incontinence in people with chronic heart failure. Heart Lung. 2013;42:154.PubMedCrossRef
14.
Holzmann MJ, Gardell C, Jeppsson A, Sartipy U. Renal dysfunction and long-term risk of heart failure after coronary artery bypass grafting. Am Heart J. 2013;166:142–9.PubMedCrossRef
15.
Balta S, Demirkol S, Karaman M. Renal dysfunction may predict new onset heart failure. Am Heart J. 2013;166:e5.PubMedCrossRef
16.
Kim HN, Januzzi JL Jr. Biomarkers in the management of heart failure. Curr Treat Options Cardiovasc Med. 2010;12:519–31.PubMedCrossRef
17.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.PubMedCrossRef
18.
McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol. 2013;29:168–81.PubMedCrossRef
19.
Yoshimura K, Nakayama T, Sekine A, Matsuda F, Kosugi S, Yamada R, et al. B-Type natriuretic peptide as an independent correlate of nocturnal voiding in Japanese women. Neurourol Urodyn. 2012;31:1266–71.PubMedCrossRef
20.
Adorisio R, De Luca L, Rossi J, Gheorghiade M. Pharmacological treatment of chronic heart failure. Heart Fail Rev. 2006;11:109–23.PubMedCrossRef
21.
Kashyap M, Tu LM, Tannenbaum C. Prevalence of commonly prescribed medications potentially contributing to urinary symptoms in a cohort of older patients seeking care for incontinence. BMC Geriatr. 2013;13:57.PubMedCentralPubMedCrossRef
22.
23.
Hall SA, Chiu GR, Kaufman DW, Wittert GA, Link CL, McKinlay JB. Commonly used antihypertensives and lower urinary tract symptoms: results from the Boston Area Community Health (BACH) Survey. BJU Int. 2012;109:1676–84.PubMedCentralPubMedCrossRef
24.
Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;(2):CD003838.
25.
Patterson JH, Adams KF Jr, Applefeld MM, Corder CN, Masse BR. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy. 1994;14:514–21.PubMed
26.
Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94:573–80.PubMedCrossRef
27.
Ekundayo OJ. The association between overactive bladder and diuretic use in the elderly. Curr Urol Rep. 2009;10:434–40.PubMedCrossRef
28.
Ekundayo OJ, Markland A, Lefante C, Sui X, Goode PS, Allman RM, et al. Association of diuretic use and overactive bladder syndrome in older adults: a propensity score analysis. Arch Gerontol Geriatr. 2009;49:64–8.PubMedCentralPubMedCrossRef
29.
Finkelstein MM. Medical conditions, medications, and urinary incontinence: analysis of a population-based survey. Can Fam Physician: Medecin de famille canadien. 2002;48:96–101.PubMed
30.
Ruby CM, Hanlon JT, Fillenbaum GG, Pieper CF, Branch LG, Bump RC. Medication use and control of urination among community-dwelling older adults. J Aging Health. 2005;17:661–74.PubMedCrossRef
31.
Ruby CM, Hanlon JT, Boudreau RM, Newman AB, Simonsick EM, Shorr RI, et al. The effect of medication use on urinary incontinence in community-dwelling elderly women. J Am Geriatr Soc. 2010;58:1715–20.PubMedCentralPubMedCrossRef
32.
Diokno AC, Brown MB, Herzog AR. Relationship between use of diuretics and continence status in the elderly. Urology. 1991;38:39–42.PubMedCrossRef
33.
Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527–34.PubMedCrossRef
34.
Dormans TP, Gerlag PG, Russel FG, Smits P. Combination diuretic therapy in severe congestive heart failure. Drugs. 1998;55:165–72.PubMedCrossRef
35.
Kazi D, Deswal A. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. Cardiol Clin. 2008;26:1–14, v.
36.
Poole MD, Postma DS. Characterization of cough associated with angiotensin-converting enzyme inhibitors. Otolaryngol Head Neck Surg. 1991;105:714–6.PubMed
37.
Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:169S–73S.PubMedCrossRef
38.
Menefee SA, Chesson R, Wall LL. Stress urinary incontinence due to prescription medications: alpha-blockers and angiotensin converting enzyme inhibitors. Obstet Gynecol. 1998;91:853–4.PubMedCrossRef
39.
Casanova JE. Incontinence after use of enalapril. J Urol. 1990;143:1237–8.PubMed
40.
Lee YJ, Chiang YF, Tsai JC. Severe nonproductive cough and cough-induced stress urinary incontinence in diabetic postmenopausal women treated with ACE inhibitor. Diabetes Care. 2000;23:427–8.PubMedCrossRef
41.
Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. JAMA. 2002;287:883–9.PubMedCrossRef
42.
Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747–62.PubMedCrossRef
43.
Lewandowski J, Sinski M, Symonides B, Korecki J, Rogowski K, Judycki J, et al. Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study. Urology. 2013;82:660–6.PubMedCrossRef
44.
Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol. 1999;162:376–82.PubMedCrossRef
45.
Peron EP, Zheng Y, Perera S, Newman AB, Resnick NM, Shorr RI, et al. Antihypertensive drug class use and differential risk of urinary incontinence in community-dwelling older women. J Gerontol A Biol Sci Med Sci. 2012;67:1373–8.PubMedCrossRef
46.
Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62:1040–60.PubMedCrossRef
47.
Cui Y, Zong H, Yang C, Yan H, Zhang Y. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. Epub 30 Jul 2013.
48.
Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011;72:186–96.PubMedCrossRef
49.
Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010;106:268–74.PubMedCrossRef
50.
Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU Int. 2012;109:572–80.PubMedCrossRef
51.
Andersson KE, Martin N, Nitti V. Selective beta-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013;190(4):1173–80.
52.
Graves T, Hanlon JT, Schmader KE, Landsman PB, Samsa GP, Pieper CF, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med. 1997;157:2205–10.PubMedCrossRef
53.
Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012;(4):CD003040.
54.
Gavazzi G, Delerce E, Cambau E, Francois P, Corroyer B, de Wazieres B, et al. Diagnostic criteria for urinary tract infection in hospitalized elderly patients over 75 years of age: a multicenter cross-sectional study. Med Mal Infect. 2013;43:189–94.PubMedCrossRef
55.
Bulger J, Nickel W, Messler J, Goldstein J, O’Callaghan J, Auron M, et al. Choosing wisely in adult hospital medicine: five opportunities for improved healthcare value. J Hosp Med. 2013;8(9):486–92.
56.
Johnell K, Fastbom J. The use of benzodiazepines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics. Int J Geriatr Psychiatry. 2009;24:731–8.PubMedCrossRef
57.
Halme AS, Beland SG, Preville M, Tannenbaum C. Uncovering the source of new benzodiazepine prescriptions in community-dwelling older adults. Int J Geriatr Psychiatry. 2013;28:248–55.PubMedCrossRef
58.
Landi F, Cesari M, Russo A, Onder G, Sgadari A, Bernabei R. Benzodiazepines and the risk of urinary incontinence in frail older persons living in the community. Clin Pharmacol Ther. 2002;72:729–34.PubMedCrossRef
59.
Andrews LK, Coviello J, Hurley E, Rose L, Redeker NS. “I’d eat a bucket of nails if you told me it would help me sleep:” perceptions of insomnia and its treatment in patients with stable heart failure. Heart Lung. 2013;42:339–45.PubMedCrossRef
60.
Wright SP, Walsh H, Ingley KM, Muncaster SA, Gamble GD, Pearl A, et al. Uptake of self-management strategies in a heart failure management programme. Eur J Heart Fail. 2003;5:371–80.PubMedCrossRef
61.
Holroyd-Leduc JM, Straus S, Thorpe K, Davis DA, Schmaltz H, Tannenbaum C. Translation of evidence into a self-management tool for use by women with urinary incontinence. Age Ageing. 2011;40:227–33.PubMedCrossRef
62.
63.
Dereppe H, Hoylaerts M, Renard M, Leduc O, Bernard R, Leduc A. Hemodynamic impact of pressotherapy [in French]. J Mal Vasc. 1990;15:267–9.PubMed
64.
Lohsiriwat S, Hirunsai M, Chaiyaprasithi B. Effect of caffeine on bladder function in patients with overactive bladder symptoms. Urol Ann. 2011;3:14–8.PubMedCentralPubMedCrossRef
65.
Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstet Gynecol. 2000;96:85–9.PubMedCrossRef
66.
Davis NJ, Vaughan CP, Johnson TM 2nd, Goode PS, Burgio KL, Redden DT, et al. Caffeine intake and its association with urinary incontinence in United States men: results from National Health and Nutrition Examination Surveys 2005–2006 and 2007–2008. J Urol. 2013;189:2170–4.PubMedCrossRef
67.
Gleason JL, Richter HE, Redden DT, Goode PS, Burgio KL, Markland AD. Caffeine and urinary incontinence in US women. Int Urogynecol J. 2013;24:295–302.PubMedCentralPubMedCrossRef
68.
Jura YH, Townsend MK, Curhan GC, Resnick NM, Grodstein F. Caffeine intake, and the risk of stress, urgency and mixed urinary incontinence. J Urol. 2011;185:1775–80.PubMedCentralPubMedCrossRef
69.
Paterna S, Fasullo S, Parrinello G, Cannizzaro S, Basile I, Vitrano G, et al. Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association class III (Class C) (SMAC-HF Study). Am J Med Sci. 2011;342:27–37.PubMedCrossRef
70.
Gargiulo G, Testa G, Cacciatore F, Mazzella F, Galizia G, Della-Morte D, et al. Moderate alcohol consumption predicts long-term mortality in elderly subjects with chronic heart failure. J Nutr Health Aging. 2013;17:480–5.PubMedCrossRef
71.
Hay-Smith EJ, Herderschee R, Dumoulin C, Herbison GP. Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev. 2011;(12):CD009508.
72.
Shamliyan T, Wyman J, Kane RL. Nonsurgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness. Rockville, MD; 2012.
73.
Herderschee R, Hay-Smith EC, Herbison GP, Roovers JP, Heineman MJ. Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women: shortened version of a Cochrane systematic review. Neurourol Urodyn. 2013;32:325–9.PubMedCrossRef
74.
Johnell K, Fastbom J, Rosen M, Leimanis A. Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother. 2007;41:1243–8.PubMedCrossRef
75.
Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110:1767–74.PubMedCrossRef
Metadata
Title
Managing Therapeutic Competition in Patients with Heart Failure, Lower Urinary Tract Symptoms and Incontinence
Authors
Cara Tannenbaum
Kristina Johnell
Publication date
01-02-2014
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 2/2014
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-013-0145-1

Other articles of this Issue 2/2014

Drugs & Aging 2/2014 Go to the issue

Original Research Article

Consensus Validation of the FORTA (Fit fOR The Aged) List: A Clinical Tool for Increasing the Appropriateness of Pharmacotherapy in the Elderly

Review Article

The Association Between Drugs Frequently Used by the Elderly and Vitamin D Blood Levels: A Review of Observational and Experimental Studies

Review Article

Quality of Life of Older Patients Undergoing Renal Transplantation: Finding the Right Immunosuppressive Treatment

Therapy in Practice

Postoperative Pain Management After Total Knee Arthroplasty in Elderly Patients: Treatment Options

Original Research Article

Influence of Urban Residence on Use of Psychotropic Medications in Pennsylvania, USA: Cross-sectional Comparison of Older Adults Attending Senior Centers

Short Communication

Medication for Alzheimer’s Disease and Associated Fall Hazard: A Retrospective Cohort Study from the Alzheimer’s Disease Neuroimaging Initiative
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits